Pieris Pharmaceuticals

Pieris Pharmaceuticals company information, Employees & Contact Information

In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics, Inc. (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com

Company Details

Employees
20
Founded
-
Address
225 Franklin Street, Boston,massachusetts 02110,united States
Phone
118572468998
Email
in****@****ris.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
pieris.com
HQ
Boston, Massachusetts
Looking for a particular Pieris Pharmaceuticals employee's phone or email?

Pieris Pharmaceuticals Questions

News

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - ACCESS Newswire

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific ACCESS Newswire

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement - Yahoo Finance

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Yahoo Finance

Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022 - FinancialContent

Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022 FinancialContent

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split - Yahoo Finance

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Yahoo Finance

Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains - Frontiers

Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains Frontiers

Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis - MarketBeat

Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis MarketBeat

Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study - Yahoo Finance

Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study Yahoo Finance

Top Pieris Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant